Brief: BeyondSpring Gives Positive Data With Plinabulin For Prevention Of Docetaxel-Induced Neutropenia
13/12/2022 13:23
Dec 13 (Reuters) - BeyondSpring Inc BYSI.O :
* BEYONDSPRING PRESENTS POSITIVE DATA WITH PLINABULIN FOR
THE
PREVENTION OF DOCETAXEL-INDUCED NEUTROPENIA IN PATIENTS WITH
NON-SMALL CELL LUNG CANCER AND BREAST CANCER AT THREE MEDICAL
CONFERENCES
Source text for Eikon: ID:nGNX7zMNkZ
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value